Papillary Fibroelastoma (PFE) 101

<p>Papillary Fibroelastoma (PFE)</p> <p>Guest: Kyle W. Klarich, M.D. (<a href='https://twitter.com/KyleWKlarich'>@KyleWKlarich</a>)</p> <p>Host: Paul A. Friedman, M.D. (<a href='https://twitter.com/drpaulfriedman'>@drpaulfriedman</a>)</p> <p>Papillary fibroelastomas (PFEs) are the most common benign neoplasms of the cardiac valvular structures. Although rare and often hard to diagnose accurately, PFEs are being recognized more frequently via high-resolution imaging technology — and by ruling out other possible conditions that can mimic them.</p> <p>Joining us today to discuss papillary fibroelastomas is Kyle W. Klarich, M.D., a consultant in Cardiovascular Medicine with a joint appointment in the Echocardiography Laboratory here at Mayo  Clinic in Rochester, Minnesota. Dr. Klarich is also Vice Chair for Clinical Practice in the Department of Cardiovascular Medicine, echocardiology specialist, and a professor of medicine at Mayo Clinic College of Medicine and Science.</p> <p>Specific topics discussed:</p> <ul><li>Papillary fibroelastoma (PFE) explained</li> <li>Best approaches to PFE identification: echocardiography, physical exam and antinuclear antibody testing</li> <li>PFE or nonbacterial thrombotic endocarditis</li> <li>Risk assessment and treatment alternatives</li> <li>New forms of treatment: a percutaneous solution</li> </ul> <p>Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at <a href='https://cveducation.mayo.edu'>https://cveducation.mayo.edu</a> or on Twitter <a href='https://www.twitter.com/mayocliniccv'>@MayoClinicCV</a>.</p> <p>No CME credit offered for this episode.</p> <p>Podcast transcript can be found <a href='https://mcdn.podbean.com/mf/web/sxfs7f/P-MayoCV04_Papillary_Fibroelastoma_PFE__Friedman-Klarich_CC_Transcript_Final9vcx0.pdf'>here</a>.</p>